Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity

Molecular Cancer Research

Volumn 11, Issue 12, 2013, Pages 1564-1573

  Huang, Jen Wei ^a,b   Wang, Yemin ^a,b   Dhillon, Kiranjit K ^a,b   Calses, Philamer ^a,b   Villegas, Emily ^b   Mitchell, Patrick S ^b   Tewari, Muneesh ^b,c   Kemp, Christopher J ^b   Taniguchi, Toshiyasu ^a,b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; MESSENGER RNA; MICRORNA; MICRORNA 103; MICRORNA 107; OLAPARIB; RAD51 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHEMOSENSITIVITY; FEMALE; GENOMIC INSTABILITY; HELA CELL; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; LUNG ADENOCARCINOMA; OSTEOSARCOMA; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; WESTERN BLOTTING;

CELL LINE, TUMOR; CISPLATIN; DNA BREAKS, DOUBLE-STRANDED; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HELA CELLS; HUMANS; MICRORNAS; OSTEOSARCOMA; PHTHALAZINES; PIPERAZINES; RAD51 RECOMBINASE; RECOMBINATIONAL DNA REPAIR;

EID: 84891369796     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0292     Document Type: Article

References (50)

1. Heyer WD, Ehmsen KT, Liu J. Regulation of homologous recombination in eukaryotes. Annu Rev Genet 2010;44:113-39.
2. Haaf T, Golub EI, Reddy G, Radding CM, Ward DC. Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes. Proc Natl Acad Sci U S A 1995;92:2298-302.
3. Suwaki N, Klare K, Tarsounas M. RAD51 paralogs: roles in DNA damage signalling, recombinational repair, and tumorigenesis. Semin Cell Dev Biol 2011;22:898-905.
4. Chun J, Buechelmaier ES, Powell SN. Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway. Mol Cell Biol 2013;33: 387-95.
5. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011;108:18032-7.
6. Evers B, Helleday T, Jonkers J. Targeting homologous recombination repair defects in cancer. Trends Pharmacol Sci 2010;31:372-80.
7. Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J Pathol 2011;223:102-15.
8. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalianmRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
9. Chowdhury D, Choi YE, Brault ME. Charity begins at home: noncoding RNA functions in DNA repair. Nat Rev Mol Cell Biol 2013;14: 181-9.
10. Wang Y, Taniguchi T. MicroRNAs and DNA damage response: implications for cancer therapy. Cell Cycle 2013;12:32-42.
11. Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, et al. Downregulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med 2011;3:279-90.
12. Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O'Day E, et al. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cellcycle genes via binding to "seedless" 30UTR microRNA recognition elements. Mol Cell 2009;35:610-25.
13. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011;41: 210-20.
14. Song L, Dai T, Xie Y, Wang C, Lin C, Wu Z, et al. Upregulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair. J Mol Cell Biol 2012;4:108-17.
15. Lal A, Pan Y, Navarro F, Dykxhoorn DM, Moreau L, Meire E, et al. miR-24-mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nat Struct Mol Biol 2009;16:492-8.
16. Wang Y, Huang JW, Li M, Cavenee WK, Mitchell PS, Zhou X, et al. MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol Cancer Res 2011;9:1100-11.
17. Wang Y, Huang JW, Calses P, Kemp CJ, Taniguchi T. MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res 2012;72:4037-46.
18. Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 2009;69:6381-6.
19. Hine CM, Seluanov A, Gorbunova V. Use of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl Acad Sci U S A 2008;105: 20810-5.
20. Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS ONE 2009;4:e6529.
21. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451:1116-20.
22. Yata K, Lloyd J, Maslen S, Bleuyard JY, Skehel M, Smerdon SJ, et al. Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair. Mol Cell 2012;45:371-83.
23. Weinstock DM, Nakanishi K, Helgadottir HR, Jasin M. Assaying double-strand break repair pathway choice in mammalian cells using a targeted endonuclease or the RAG recombinase. Methods Enzymol 2006;409:524-40.
24. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, et al. Micro-RNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol 2008;110:206-15.
25. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, et al. MicroRNA profiling in kidney and bladder cancers. Urol Oncol 2007;25:387-92.
26. Lee KH, Lotterman C, Karikari C, Omura N, Feldmann G, Habbe N, et al. Epigenetic silencing of microRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 2009;9:293-301.
27. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006;24:4677-84.
28. Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO, Yasuda J. MiR-107 and MiR-185 can induce cell-cycle arrest in human non-small cell lung cancer cell lines. PLoS ONE 2009;4:e6677.
29. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, et al. A microRNA targeting dicer for metastasis control. Cell 2010;141:1195-207.
30. Bohlig L, Friedrich M, Engeland K. p53 activates the PANK1/miRNA-107 gene leading to downregulation of CDK6 and p130 cell-cycle proteins. Nucleic Acids Res 2011;39:440-53.
31. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNAprocessing by p53. Nature 2009;460:529-33.
32. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A 2010;107:6334-9.
33. Huertas P, Jackson SP. Human CtIP mediates cell-cycle control of DNA end resection and double strand break repair. J Biol Chem 2009;284:9558-65.
34. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are micro-RNA targets. Cell 2005;120:15-20.
35. Chen PS, Su JL, Cha ST, Tarn WY, Wang MY, Hsu HC, et al. miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. J Clin Invest 2011;121:3442-55.
36. Selcuklu SD, Yakicier MC, Erson AE. An investigation of microRNAs mapping to breast cancer related genomic gain and loss regions. Cancer Genet Cytogenet 2009;189:15-23.
37. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 2012;72:3499-511.
38. Munshi NC, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2004;103:1799-806.
39. Yoshikawa K, Ogawa T, Baer R, Hemmi H, Honda K, Yamauchi A, et al. Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas. Int J Cancer 2000;88:28-36.
40. Kato M, Yano K, Matsuo F, Saito H, Katagiri T, Kurumizaka H, et al. Identification of Rad51 alteration in patients with bilateral breast cancer. J Hum Genet 2000;45:133-7.
41. Somyajit K, Basavaraju S, Scully R, Nagaraju G. ATM-and ATRmediated phosphorylation of XRCC3 regulates DNA double-strand break-induced checkpoint activation and repair. Mol Cell Biol 2013;33:1830-44.
42. Shu J, Kren BT, Xia Z, Wong PY, Li L, Hanse EA, et al. Genomewide microRNA downregulation as a negative feedback mechanism in the early phases of liver regeneration. Hepatology 2011;54:609-19.
43. Pouliot LM, Shen DW, Suzuki T, Hall MD, Gottesman MM. Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells. Exp Cell Res 2013;319:566-74.
44. Francia S, Michelini F, Saxena A, Tang D, de Hoon M, Anelli V, et al. Site-specific DICER and DROSHA RNA products control the DNAdamage response. Nature 2012;488:231-5.
45. Wei W, Ba Z, Gao M, Wu Y, Ma Y, Amiard S, et al. A role for small RNAs in DNA double-strand break repair. Cell 2012;149:101-12.
46. Annibali D, Gioia U, Savino M, Laneve P, Caffarelli E, Nasi S. A new module in neural differentiation control: two microRNAs upregulated by retinoic acid, miR-9 and-103, target the differentiation inhibitor ID2. PLoS ONE 2012;7:e40269.
47. Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A, et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007;26:4148-57.
48. Liao Y, Lonnerdal B. Global microRNA characterization reveals that miR-103 is involved in IGF-1 stimulated mouse intestinal cell proliferation. PLoS ONE 2010;5:e12976.
49. Piao L, Zhang M, Datta J, Xie X, Su T, Li H, et al. Lipid-based nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol Ther 2012;20: 1261-9.
50. Neijenhuis S, Bajrami I, Miller R, Lord CJ, Ashworth A. Identification of miRNA modulators to PARP inhibitor response. DNA Repair 2013; 12:394-402.